ALT - Altimmune - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALT is currently covered by 6 analysts with an average price target of $15.22. This is a potential upside of $11.53 (312.47%) from yesterday's end of day stock price of $3.69.

Altimmune's activity chart (see below) currently has 65 price targets and 81 ratings on display. The stock rating distribution of ALT is 88.89% BUY, 7.41% HOLD and 3.7% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 12.14% with an average time for these price targets to be met of 35.1 days.

Highest price target for ALT is $20, Lowest price target is $1, average price target is $14.6.

Most recent stock forecast was given by JONATHAN WOLLEBEN from JMP on 10-Jul-2025. First documented stock forecast 01-Jun-2020.

Currently out of the existing stock ratings of ALT, 24 are a BUY (88.89%), 2 are a HOLD (7.41%), 1 are a SELL (3.7%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$11.31 (306.50%)

$25

23 days ago
(10-Jul-2025)

0/16 (0%)

$10.6 (240.91%)

Sell

$1

$-2.69 (-72.90%)

$13

23 days ago
(10-Jul-2025)

1/4 (25%)

$-3.4 (-77.27%)

34

Buy

$12

$8.31 (225.20%)

$12

1 months 6 days ago
(27-Jun-2025)

0/18 (0%)

$8.5 (242.86%)

Buy

$20

$16.31 (442.01%)

$20

11 months 21 days ago
(12-Aug-2024)

4/16 (25%)

$13.78 (221.54%)

214

Buy

$25

$21.31 (577.51%)

$25

1 years 1 months 12 days ago
(21-Jun-2024)

3/14 (21.43%)

$18.59 (290.02%)

42

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALT (Altimmune) average time for price targets to be met?

On average it took 35.1 days on average for the stock forecasts to be realized with a an average price target met ratio 12.14

Which analyst has the current highest performing score on ALT (Altimmune) with a proven track record?

MAYANK MAMTANI

Which analyst has the most public recommendations on ALT (Altimmune)?

Mayank Mamtani works at B. RILEY and has 2 price targets and 1 ratings on ALT

Which analyst is the currently most bullish on ALT (Altimmune)?

Roger Song with highest potential upside - $28.34

Which analyst is the currently most reserved on ALT (Altimmune)?

Corinne Jenkins with lowest potential downside - -$2.69

Altimmune in the News

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress™ in Amsterdam, The Netherlands. The presentation focuses on the use of...

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index (MASHResInd; Loomba 2024), a highly sensitive...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?